-
Product Insights
New![]()
Net Present Value Model: Mesoblast Ltd’s Rexlemestrocel-L
Overview Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Company Insights
Legal and General (L&G) – Digital Transformation Strategies
Legal & General (L&G) Digital Transformation Strategies Report Overview Legal & General (L&G) has been focusing on emerging technologies as a part of its digital transformation strategies. The annual ICT spending of L&G was estimated at $391.9 million in 2022. A major share of this spending is earmarked for acquiring software, hardware, and consulting from vendors. L&G provides insurance, saving, and investment products, it offers individual and group protection plans, annuities, mortgages, pension plans, and general insurance products. Total ICT...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – L-130 in Anxiety Disorders
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. L-130 in Anxiety Disorders Drug Details: L-130 is under development for the treatment of severe...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – hepcortespenlisimut-L in Hepatocellular Carcinoma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Hepcortespenlisimut-L in Hepatocellular Carcinoma Drug Details:Hepcortespenlisimut-L (V5) is under development for the treatment of hepatocellular carcinoma....
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – DCVax-L in Peritoneal Cancer
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. DCVax-L in Peritoneal Cancer Drug Details: DCVax-L contains autologous, antigen-presenting dendritic cells. It is...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Remestemcel-L in Ulcerative Colitis
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Remestemcel-L in Ulcerative Colitis Drug Details: Remestemcel-L (Prochymal, Temcell) is a stem cell drug therapy....
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Rexlemestrocel-L in Chronic Heart Failure
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Rexlemestrocel-L in Chronic Heart Failure Drug Details: Rexlemestrocel-L is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Rexlemestrocel-L in Left Ventricular Dysfunction
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Rexlemestrocel-L in Left Ventricular Dysfunction Drug Details: Rexlemestrocel-L is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – DCVax-L in Metastatic Ovarian Cancer
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. DCVax-L in Metastatic Ovarian Cancer Drug Details: DCVax-L contains autologous, antigen-presenting dendritic cells. It...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – DCVax-L in Epithelial Ovarian Cancer
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. DCVax-L in Epithelial Ovarian Cancer Drug Details: DCVax-L contains autologous, antigen-presenting dendritic cells. It...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Cenplacel-L in Crohn’s Disease (Regional Enteritis)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Cenplacel-L in Crohn's Disease (Regional Enteritis)Drug Details:Cenplacel-L (PDA-001) is under development for the treatment of Crohn’s...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – VYAADC-01 in Aromatic l-Amino Acid Decarboxylase (AADC) Deficiency
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. VYAADC-01 in Aromatic l-Amino Acid Decarboxylase (AADC) Deficiency Drug Details: VYAADC-01 is under development...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – GT-0002X in Aromatic l-Amino Acid Decarboxylase (AADC) Deficiency
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.GT-0002X in Aromatic l-Amino Acid Decarboxylase (AADC) DeficiencyDrug Details:Gene therapy is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Eladocagene Exuparvovec in Aromatic l-Amino Acid Decarboxylase (AADC) Deficiency
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Eladocagene Exuparvovec in Aromatic l-Amino Acid Decarboxylase (AADC) DeficiencyDrug Details:Eladocagene exuparvovec (Upstaza) is a gene therapy...
-
Product Insights
L & L Dev – La Loma Residential Tower – Colorado
Equip yourself with the essential tools needed to make informed and profitable decisions with our L & L Dev - La Loma Residential Tower - Colorado report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story: Dive...
-
Product Insights
L&L Invts/ Solstice Ptnrs – Eastport Apartment Complex – Maryland
Equip yourself with the essential tools needed to make informed and profitable decisions with our L&L Invts/ Solstice Ptnrs - Eastport Apartment Complex - Maryland report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story: Dive deep...
-
Product Insights
L&L Hldg/ Oak Row Equities – The Wynwood Plaza – Florida
Equip yourself with the essential tools needed to make informed and profitable decisions with our L&L Hldg/ Oak Row Equities - The Wynwood Plaza - Florida report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story: Dive...
-
Product Insights
Carpe RE/ L&L Hldg – Rubell Mixed-Use Complex – Florida
Equip yourself with the essential tools needed to make informed and profitable decisions with our Carpe RE/ L&L Hldg - Rubell Mixed-Use Complex - Florida report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story: Dive deep...
-
Product Insights
Carpe RE/ L&L Hldg – Wynwood Plaza Mixed-Use Development – Florida
Equip yourself with the essential tools needed to make informed and profitable decisions with our Carpe RE/ L&L Hldg - Wynwood Plaza Mixed-Use Development - Florida report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story: Dive...
-
Product Insights
Columbia Property/ L&L Hldg – 261 Eleventh Avenue Commercial Tower – New York
Equip yourself with the essential tools needed to make informed and profitable decisions with our Columbia Property/ L&L Hldg - 261 Eleventh Avenue Commercial Tower - New York report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.